ArticleClinical pharmacology and therapeutics2011
From treating complex coronary artery disease to promoting cardiovascular health: therapeutic transitions and challenges, 2010-2020.
Article in Clinical pharmacology and therapeutics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 29 citations in OpenAlex.
- Water-soluble acacetin prodrug confers significant cardioprotection against ischemia/reperfusion injury.Scientific reports · 2016Article
- "Second-generation" stem cells for cardiac repair.World journal of stem cells · 2015Review
- Sulforaphane Protects against Cardiovascular Disease via Nrf2 Activation.Oxidative medicine and cellular longevity · 2015Review
- Acute coronary syndromes: pathology, diagnosis, genetics, prevention, and treatment.Circulation research · 2014Article
- Comparison of six risk scores in patients with triple vessel coronary artery disease undergoing PCI: competing factors influence mortality, myocardial infarction, and target lesion revascularization.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2013Article
- Inflammation, heart disease, and depression.Current psychiatry reports · 2013Review
- Smoking gun theory: angiographically normal or mild coronary plaque as a cause of myocardial infarction.Circulation · 2012Article
- Vascular calcification, diabetes, and cardiovascular disease: connecting the dots.JACC. Cardiovascular imaging · 2012Article
- Cardiovascular defense challenges at the basic, clinical, and population levels.Annals of the New York Academy of Sciences · 2012Review
- Hypothyroidism in acute coronary syndrome - A prospective Indian study.Indian heart journalArticle
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
Cardiovascular disease (CVD) has become the most common cause of mortality worldwide. Obesity, insufficient physical exercise, diabetes, and advancing age are major risk factors for developing cardiovascular disease that are currently increasing in prevalence. Nevertheless, significant progress has recently been made in the treatment of complex cardiovascular and coronary artery disease (CAD), with pharmacological management set to assume an increasingly important role. Other timely factors, such as the development of the polypill and high-level medical and political interest in advancing cardiovascular health, are driving forces that may help to make inroads into the global cardiovascular disease burden. In this article, we critically review the key challenges that we face in the coming decade as we strive to transition and apply our growing knowledge of complex CAD to promoting global cardiovascular health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.